@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix nkg: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin d to control hypocalcemia in patients with hypoparathyroidism limitations of use because of the potential risk of osteosarcoma natpara is recommended only for patients who cannot be well controlled on calcium supplements and active forms of vitamin d alone see warnings and precautions 5 1 natpara was not studied in patients with hypoparathyroidism caused by calcium sensing receptor mutations natpara was not studied in patients with acute post surgical hypoparathyroidism natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin d to control hypocalcemia in patients with hypoparathyroidism 1 limitations of use because of the potential risk of osteosarcoma natpara is recommended only for patients who cannot be well controlled on calcium supplements and active forms of vitamin d alone 5 1 natpara was not studied in patients with hypoparathyroidism caused by calcium sensing receptor mutations natpara was not studied in patients with acute post surgical hypoparathyroidism";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation nkg:SymptomaticReliefIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "OjEIvct5ODrMNwJHKghKR/2mt8PlSD6/Z3CTOg7eRje8iDGgIRI7dCzdB/n1K6PaSlhLdrIFxoizYTJnTPg92AN+CQYvaFvpba6Cq1WQnKGC8gaUiIjKhntp/n+yuD7E7Ttr761kItdFkdGivMKs7dn+aTbA+qMuyp0tLj5YZ0o=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-07-03T14:51:17.432+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}